Combination of | |
---|---|
Umeclidinium bromide | Muscarinic antagonist |
Vilanterol | Ultra-long-acting β2 agonist |
Clinical data | |
Trade names | Anoro Ellipta, Laventair Ellipta |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD).[4][5] It is administered by inhalation.
The most common side effects include upper respiratory tract infections, urinary tract infections, pharyngitis, sinusitis, nasopharyngitis, headache, cough, oropharyngeal pain, constipation and dry mouth.[3]
In 2021, it was the 212th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[6][7]